Abstract
Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.
Originalsprog | Engelsk |
---|---|
Tidsskrift | B M C Nephrology |
Vol/bind | 11 |
Sider (fra-til) | 29 |
ISSN | 1471-2369 |
DOI | |
Status | Udgivet - 1 jan. 2010 |